ANDA 210010, held by Strides Pharma. Ranitidine Hydrochloride.
As of Nov 15, 2026, ANDA 210010 (Ranitidine Hydrochloride), held by Strides Pharma, was first approved by FDA on Aug 1, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 1, 2018 | Original application | Approved | None posted |
| Ranitidine HydrochlorideEQ 150MG BASE · tablet;oral | Ranitidine Hydrochloride | Discontinued |
| Ranitidine HydrochlorideEQ 300MG BASE · tablet;oral | Ranitidine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
